Your browser doesn't support javascript.
loading
Profiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection.
Hammers, Dustin B; Eloyan, Ani; Taurone, Alexander; Thangarajah, Maryanne; Beckett, Laurel; Gao, Sujuan; Kirby, Kala; Aisen, Paul; Dage, Jeffrey L; Foroud, Tatiana; Griffin, Percy; Grinberg, Lea T; Jack, Clifford R; Kramer, Joel; Koeppe, Robert; Kukull, Walter A; Mundada, Nidhi S; La Joie, Renaud; Soleimani-Meigooni, David N; Iaccarino, Leonardo; Murray, Melissa E; Nudelman, Kelly; Polsinelli, Angelina J; Rumbaugh, Malia; Toga, Arthur; Touroutoglou, Alexandra; Vemuri, Prashanthi; Atri, Alireza; Day, Gregory S; Duara, Ranjan; Graff-Radford, Neill R; Honig, Lawrence S; Jones, David T; Masdeu, Joseph; Mendez, Mario F; Womack, Kyle; Musiek, Erik; Onyike, Chiadi U; Riddle, Meghan; Rogalski, Emily; Salloway, Steven; Sha, Sharon J; Turner, Raymond Scott; Wingo, Thomas S; Wolk, David A; Carrillo, Maria C; Dickerson, Bradford C; Rabinovici, Gil D; Apostolova, Liana G.
Affiliation
  • Hammers DB; Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Eloyan A; Department of Biostatistics, Center for Statistical Sciences, Brown University, Providence, Rhode Island, USA.
  • Taurone A; Department of Biostatistics, Center for Statistical Sciences, Brown University, Providence, Rhode Island, USA.
  • Thangarajah M; Department of Biostatistics, Center for Statistical Sciences, Brown University, Providence, Rhode Island, USA.
  • Beckett L; Department of Public Health Sciences, University of California - Davis, Davis, California, USA.
  • Gao S; Department of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Kirby K; Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Aisen P; Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
  • Dage JL; Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Foroud T; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Griffin P; Medical & Scientific Relations Division, Alzheimer's Association, Chicago, Illinois, USA.
  • Grinberg LT; Department of Pathology, University of California - San Francisco, San Francisco, California, USA.
  • Jack CR; Department of Neurology, University of California - San Francisco, San Francisco, California, USA.
  • Kramer J; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Koeppe R; Department of Neurology, University of California - San Francisco, San Francisco, California, USA.
  • Kukull WA; Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA.
  • Mundada NS; Department of Epidemiology, University of Washington, Seattle, Washington, USA.
  • La Joie R; Department of Neurology, University of California - San Francisco, San Francisco, California, USA.
  • Soleimani-Meigooni DN; Department of Neurology, University of California - San Francisco, San Francisco, California, USA.
  • Iaccarino L; Department of Neurology, University of California - San Francisco, San Francisco, California, USA.
  • Murray ME; Department of Neurology, University of California - San Francisco, San Francisco, California, USA.
  • Nudelman K; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
  • Polsinelli AJ; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Rumbaugh M; Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Toga A; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Touroutoglou A; Laboratory of Neuro Imaging, USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, Los Angeles, California, USA.
  • Vemuri P; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Atri A; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Day GS; Banner Sun Health Research Institute, Sun City, Arizona, USA.
  • Duara R; Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
  • Graff-Radford NR; Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami, Florida, USA.
  • Honig LS; Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
  • Jones DT; Taub Institute and Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA.
  • Masdeu J; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Mendez MF; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Womack K; Nantz National Alzheimer Center, Houston Methodist and Weill Cornell Medicine, Houston, Texas, USA.
  • Musiek E; Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Onyike CU; Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
  • Riddle M; Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
  • Rogalski E; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Salloway S; Department of Neurology, Alpert Medical School, Brown University, Providence, Rhode Island, USA.
  • Sha SJ; Department of Psychiatry and Behavioral Sciences, Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Turner RS; Department of Neurology, Alpert Medical School, Brown University, Providence, Rhode Island, USA.
  • Wingo TS; Department of Neurology & Neurological Sciences, Stanford University, Palo Alto, California, USA.
  • Wolk DA; Department of Neurology, Georgetown University, Washington D.C., USA.
  • Carrillo MC; Department of Neurology and Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Dickerson BC; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Rabinovici GD; Medical & Scientific Relations Division, Alzheimer's Association, Chicago, Illinois, USA.
  • Apostolova LG; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Alzheimers Dement ; 19 Suppl 9: S8-S18, 2023 11.
Article in En | MEDLINE | ID: mdl-37256497
ABSTRACT

OBJECTIVE:

The Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) seeks to provide comprehensive understanding of early-onset Alzheimer's disease (EOAD; onset <65 years), with the current study profiling baseline clinical, cognitive, biomarker, and genetic characteristics of the cohort nearing the data-collection mid-point.

METHODS:

Data from 371 LEADS participants were compared based on diagnostic group classification (cognitively normal [n = 89], amyloid-positive EOAD [n = 212], and amyloid-negative early-onset non-Alzheimer's disease [EOnonAD; n = 70]).

RESULTS:

Cognitive performance was worse for EOAD than other groups, and EOAD participants were apolipoprotein E (APOE) ε4 homozygotes at higher rates. An amnestic presentation was common among impaired participants (81%), with several clinical phenotypes present. LEADS participants generally consented at high rates to optional trial procedures.

CONCLUSIONS:

We present the most comprehensive baseline characterization of sporadic EOAD in the United States to date. EOAD presents with widespread cognitive impairment within and across clinical phenotypes, with differences in APOE ε4 allele carrier status appearing to be relevant. HIGHLIGHTS Findings represent the most comprehensive baseline characterization of sporadic early-onset Alzheimer's disease (EOAD) to date. Cognitive impairment was widespread for EOAD participants and more severe than other groups. EOAD participants were homozygous apolipoprotein E (APOE) ε4 carriers at higher rates than the EOnonAD group. Amnestic presentation predominated in EOAD and EOnonAD participants, but other clinical phenotypes were present.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease Type of study: Etiology_studies Limits: Humans Language: En Journal: Alzheimers Dement Year: 2023 Document type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease Type of study: Etiology_studies Limits: Humans Language: En Journal: Alzheimers Dement Year: 2023 Document type: Article Affiliation country: United States